Oral vitamin D, still a viable treatment option for psoriasis

References

• Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78:1193–1231.
   PubMed Web of Science ®Google Scholar
• Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2:203–216.
   PubMedGoogle Scholar
• Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979;206:1188–1190.
   PubMed Web of Science ®Google Scholar
• Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Endocrinology. 1983;113:1950–1957.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Kumahara Y. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ. 1985;35:51–54.
   PubMedGoogle Scholar
• Morimoto S, Yoshikawa K, Kozyka T, Kitano Y, Imanaka S, Fukuo K, An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol. 1986;115:421–429.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Yoshikawa K. Psoriasis and vitamin D3. A review of our experience. Arch Dermatol. 1989;125:231–234.
   PubMed Web of Science ®Google Scholar
• Smith EL, Pincus SH, Donovan L, Holick MF. A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis. J Am Acad Dermatol. 1988;19:516–528.
   PubMed Web of Science ®Google Scholar
• Takamoto S, Onishi T, Morimoto S, Imanaka S, Yukawa S, Kozuka T, Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: a pilot study. Calcif Tissue Int. 1986;39:360–364.
   PubMed Web of Science ®Google Scholar
• Ezquerra GM, Regana MS, Millet PU. Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis. Acta Derm Venereol. 2007;87:449–450.
   PubMed Web of Science ®Google Scholar
• Boisseau-Gersaud AM, Legrain V, Hehunstre JP, Maleville J, Taieb A. Treatment of psoriasis by oral calcitriol. A study of 5 cases and review of the literature. Ann Dermatol Venereol. 1993;120:669–674.
   PubMedGoogle Scholar
• Morimoto S, Onishi T, Imanaka S, Yukawa H, Kozuka T, Kitano Y, Topical administration of 1,25-dihydroxyvitamin D3 for psoriasis: report of five cases. Calcif Tissue Int. 1986;38:119–122.
   PubMedGoogle Scholar
• Morimoto S, Yoshikawa K, Kozuka T, Kitano Y, Imanaka S, Fukuo K, Treatment of psoriasis vulgaris with oral 1 alpha,25-dihydroxyvitamin D3–report of two cases. J Dermatol. 1987;14:59–62.
   PubMedGoogle Scholar
• Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol. 1996;134:1070–1078.
   PubMed Web of Science ®Google Scholar
• Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum. 1990;33:1723–1727.
   PubMed Web of Science ®Google Scholar
• Gaál J, Lakos G, Zodoray P, Kiss J, Horváth I, Horkay E, Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol. 2009;89:140–144.
   PubMedGoogle Scholar
• MacLaughlin JA, Gange W, Taylor D, Smith E, Holick MF. Cultured psoriatic fibroblasts from involved and uninvolved sites have a partial but not absolute resistance to the proliferation-inhibition activity of 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA. 1985;82:5409–5412.
   PubMed Web of Science ®Google Scholar
• Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221:1181–1183.
   PubMed Web of Science ®Google Scholar
• Bhalla AK, Amento EP, Serog B, Glimcher LH. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol. 1984;133:1748–1754.
   PubMed Web of Science ®Google Scholar
• Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest. 1987;79:1659–1664.
   PubMed Web of Science ®Google Scholar
• Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev. 2000;22:203–217.
   PubMed Web of Science ®Google Scholar
• Smith EL, Walworth NC, Holick MF. Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol. 1986;86:709–714.
   PubMed Web of Science ®Google Scholar
• Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol. 1999;112:113–116.
   PubMed Web of Science ®Google Scholar
• Mee JB, Cork MJ. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J Invest Dermatol. 1998;110:301–302.
   PubMed Web of Science ®Google Scholar
• Kontula K, Valimaki S, Kainulainen K, Viitanen AM, Keski-Oja J. Vitamin D receptor polymorphism and treatment of psoriasis with calcipotriol. Br J Dermatol. 1997;136:977–978.
   PubMed Web of Science ®Google Scholar
• Zhao X, Feldman D. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT−29 human colon cancer cells. Endocrinology. 1993;132:1808–1814.
   PubMed Web of Science ®Google Scholar
• Chen ML, Perez A, Sanan DK, Heinrich G, Chen TC, Holick MF. Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol. 1996;106:637–641.
   PubMed Web of Science ®Google Scholar
• Staberg B, Oxholm A, Klemp P, Christiansen C. Abnormal vitamin D metabolism in patients with psoriasis. Acta Derm Venereol. 1987;67:65–68.
   PubMed Web of Science ®Google Scholar
• Holick MF. Will 1,25-dihydroxyvitamin D3, MC 903, and their analogues herald a new pharmacologic era for the treatment of psoriasis? Arch Dermatol. 1989;125:1692–1697.
   PubMedGoogle Scholar
• Risum G. Psoriasis exacerbated by hypoparathyroidism with hypocalcaemia. Br J Dermatol. 1973;89:309–312.
   PubMedGoogle Scholar
• Stewart AF, Battaglini-Sabetta J, Millstone L. Hypocalcemia-induced pustular psoriasis of von Zumbusch. New experience with an old syndrome. Ann Intern Med. 1984;100:677–680.
   PubMed Web of Science ®Google Scholar
• Klemp P, Staberg B. Cutaneous blood flow in psoriasis. J Invest Dermatol. 1983;81:503–506.
   PubMedGoogle Scholar
• Brickman AS, Coburn JW, Friedman GR, Okamura WH, Massry SG, Norman AW. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest. 1976;57:1540–1547.
   PubMedGoogle Scholar
• van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R, Mathieu C. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation. 2000;69:1932–1942.
   PubMedGoogle Scholar
• Raisanen-Sokolowski AK, Pakkala IS, Samila SP, Binderup L, Hayry PJ, Pakkala ST. A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation. 1997;63:936–941.
   PubMed Web of Science ®Google Scholar
• Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41(3 Pt 2):S25–S28.
   PubMed Web of Science ®Google Scholar